Brief: Transcode Therapeutics Appoints Dr. Anna Moore As Chair Of Scientific Advisory Board
Brief: Transcode Therapeutics Inc - Enters Exclusive License Agreement With Unleash
Brief: Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026
Brief: Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors
Brief: TransCode Therapeutics And Quantum Leap Healthcare Collaborative Launch A Phase 2A Dose-Expansion Trial With TTX-MC138, Following Positive Readouts From TransCode's Phase 1 Trial
Brief: Transcode Therapeutics Expands Executive Team With Appointment Of Dr. Michel Janicot As Senior Development Officer
Brief: Transcode Therapeutics Completes Phase 1A Trial With TTX-MC138 In Metastatic Disease At ESMO - SEC Filing
Brief: Transcode Announces The Acquisition Of Polynoma And A $25 Mln Financing By Subsidiary Of CK Life Sciences
Brief: Transcode Therapeutics Appoints Dr. Phillip D. Zamore To Science Advisory Board
Brief: Transcode Therapeutics Announces 1-For-28 Reverse Stock Split
Brief: Transcode Therapeutics, Inc. Announces Closing Of Registered Direct Offering
Brief: TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial
Brief: Transcode Therapeutics Inc Nasdaq Determines Co Has Regained Compliance With Continued Listing Requirements
Brief: Transcode Therapeutics Announces Safety Review Committee Approval Of Opening Third Cohort And Preliminary Results From First Cohort In Phase 1 Ttx-Mc138 Trial
Brief: Transcode Therapeutics Announces Effective Date For 1-For-33 Reverse Stock Split
Brief: Transcode Therapeutics Announces 1-For-33 Reverse Stock Split
Brief: TransCode Therapeutics Completes Initial Dosing Of First Cohort In Phase 1 Clinical Trial With TTX-MC138
TransCode Therapeutics rises on US government grant for cancer therapy
Brief: Transcode Therapeutics Gets Nasdaq Minimum Bid Price Deficiency Letter